Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

被引：2

作者：

Pfeifer, Heike ^{[1
]}

Wystub, Sylvia ^{[2
]}

Binckebanck, A. ^{[1
]}

Wassmann, Barbara

Kaebisch, Andreas

Luebbert, Michael ^{[3
]}

Leimer, Lothar ^{[4
]}

Giagounidis, Aristoteles ^{[5
]}

Gassmann, Winfried ^{[6
]}

Brueck, Patrick ^{[2
]}

Serve, Hubert ^{[1
]}

Hoelzer, Dieter ^{[7
]}

Ottmann, Oliver G. ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Dept Med, D-60054 Frankfurt, Germany

[2] Goethe Univ Frankfurt, Dept Hematol, D-60054 Frankfurt, Germany

[3] Univ Hosp Freiburg, Dept Hematol & Oncol, Freiburg, Germany

[4] Robert Bosch Krankenhaus, Stuttgart, Germany

[5] St Johannes Hosp, Med Klin 2, Duisburg, Germany

[6] St Marien Krankenhaus gGmbH, Siegen, Germany

[7] Goethe Univ Hosp, Dept Internal Med Hematol & Oncol 2, Frankfurt, Germany

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.1503.1503

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1503

引用

页数：2

共 50 条

[41] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Rocha, Vanderson Geraldo
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Wang, Bingxia
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera, Josep-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[42] LONG-TERM IMPACT OF IMATINIB ON THE OUTCOME OF ALLOGENEIC TRANSPLANTATION IN ADULT PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SIMILAR OUTCOMES BETWEEN REDUCED-INTENSITY AND MYELOABLATIVE CONDITIONING TRANSPLANTS
Lee, S.
Chung, N. G.
Kwak, J. Y.
Kim, J. A.
Park, S. K.
Cho, B. S.
Kim, Y. J.
Kim, H. J.
Min, C. K.
Cho, S. G.
Kim, D. W.
Lee, J. W.
Min, W. S.
Park, C. W.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 444 - 444
[43] Post-remission therapy with imatinib and HAM improve MRD before tansplant for patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL): Results of the GRAALL AFR03 study.
Leguay, Thibaut
Witz, Francis
De Botton, Stephane
Gabert, Jean
Cayuela, Jean-Michel
Macintyre, Elizabeth
Preudhomme, Claude
Fegueux, Nathalie
Thomas, Xavier
Cahn, Jean-Yves
Escoffre, Martine
Delannoy, Andre
Ifrah, Norbert
Dombret, Herve
Pigneux, Arnaud
BLOOD, 2006, 108 (11) : 532A - 532A
[44] Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Pfeifer, Heike
Wassmann, Barbara
Pavlova, Anna
Wunderle, Lydia
Oldenburg, Johannes
Binckebanck, Anja
Lange, Thoralf
Hochhaus, Andreas
Wystub, Silvia
Brueck, Patrick
Hoelzer, Dieter
Ottmann, Oliver G.
BLOOD, 2007, 110 (02) : 727 - 734
[45] Long-term follow-up after frontline therapy with the Hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL)
Thomas, Deborah A.
Kantarjian, Hagop M.
Ravandi, Farhad
Faderl, Stefan
Garcia-Manero, Guillermo
Wierda, William
Ferrajoli, Alessandra
Vertovsek, Srdan
Jones, Dan
Letvak, Laurie
Champlin, Richard
Cortes, Jorge
O'Brien, Susan
BLOOD, 2007, 110 (11) : 10A - 11A
[46] Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Advani, Anjali S.
Moseley, Anna B.
O'Dwyer, Kristen M.
Wood, Brent L.
Park, Jae H.
Wieduwilt, Matthew J.
Jeyakumar, Deepa
Yaghmour, George
Atallah, Ehab L.
Gerds, Aaron T.
O'Brien, Susan M.
Liesveld, Jane L.
Othus, Megan
Litzow, Mark R.
Stone, Richard M.
Sharon, Elad
Yeung, Cecilia C. S.
Radich, Jerald P.
Erba, Harry P.
BLOOD, 2023, 142
[47] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
Jabbour, Elias
Martinelli, Giovanni
Vignetti, Marco
Kantarjian, Hagop
Gomez-Almaguer, David
Minami, Yosuke
Dombret, Herve
Hennessy, Meliessa
Vorog, Alexander
Wang, Bingxia
Ribera, Josep-Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
[48] Comparison of Long-Term Outcome between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia-a Multi-Center Retrospective Study
Guan, Fangshu
Yang, Luxin
Zhu, Panpan
Lai, Xiaoyu
Liu, Lizhen
Shi, Jimin
Zhao, Yanmin
Yu, Jian
Fu, Huarui
Zhao, Yi
Lan, Jianping
Chen, Yi
Lu, Ying
Ouyang, Guifang
Xu, Yang
Qiu, Xi
Cai, Zhen
Huang, He
Luo, Yi
BLOOD, 2023, 142
[49] Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph plus ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy.: an interim analysis of the GRAALL AFR09 trial.
Delannoy, A
Lhéritier, V
Thomas, X
Castaigne, S
Farhat, H
Rigal-Huguet, F
Raffoux, E
Gressin, R
Legrand, O
Witz, F
Dubruille, V
Turlure, P
Troussard, X
Delain, M
Bilhou-Nabera, C
Macintyre, E
Delabesse, E
Vernant, JP
Dombret, H
Fière, D
BLOOD, 2004, 104 (11) : 750A - 750A
[50] Imatinib plus chemotherapy in adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (PH-ALL): An exploratory cost-effectiveness analysis for the United Kingdom
Stephens, J.
Carpiuc, K. T.
Botteman, M. F.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 410 - 411

← 1 2 3 4 5 →